Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Radiotherapy versus Temozolomide in Anaplastic Glioma
2008-007295-14Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of temozolomide in anaplastic glioma, anaplastic astrocytoma (AA) and glioma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall Survival. Started Jun 2010; status: terminated.
02
Drugs
temozolomide
03
Conditions
anaplastic gliomaanaplastic astrocytoma (AA)glioma
Beyond the preview
Go deeper on 2008-007295-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007295-14.